AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11964641 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mL lidocaine combined with 1 mL triamcinolone (Group B, n=60)
Number of subjects: 120
Study 9817168 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF‐beta1 levels in bronchoalveolar lavage (BAL) fluid from sarcoidosis patients with altered lung function
Number of subjects: 73
Study 9817168 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF‐beta1 levels in BAL fluid in active sarcoidosis
Number of subjects: 73
Study 9817168 — intervention group
Group type: COMPARATOR
Intervention: TGF‐beta1 levels in BAL fluid
Number of subjects: 73
Study 9817168 — intervention group
Group type: COMPARATOR
Intervention: TGF‐beta1 levels in AM supernatants
Number of subjects: 73
Study 9817168 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of TGF‐beta1 levels in BAL with lymphocyte percentage
Number of subjects: 73
Study 9817168 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry staining of TGF‐beta1
Number of subjects: 73
Study 7623251 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac rinse (0.1%) with placebo capsule
Number of subjects: 55
Study 7623251 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic flurbiprofen (50 mg bid) with placebo rinse
Number of subjects: 55
Study 7623251 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse and capsule
Number of subjects: 55
Study 2525351 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg/kg i.v. as a bolus (30 s) before anesthesia
Number of subjects: 60
Study 2525351 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg/kg i.v. as a bolus (30 s) during anesthesia
Number of subjects: 60
Study 2525351 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg/kg i.v. as a bolus (30 s) during extracorporeal circulation (ECC)
Number of subjects: 60
Study 2525351 — intervention group
Group type: COMPARATOR
Intervention: Saline solution as placebo (control group) before anesthesia
Number of subjects: 60
Study 2525351 — intervention group
Group type: COMPARATOR
Intervention: Saline solution as placebo (control group) during anesthesia
Number of subjects: 60
Study 2525351 — intervention group
Group type: COMPARATOR
Intervention: Saline solution as placebo (control group) during ECC
Number of subjects: 60
Study 14155158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pargyline hydrochloride
Number of subjects: 25
Study 31013499 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment combined with conventional treatment (treatment group)
Number of subjects: 59
Study 31013499 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment only (control group)
Number of subjects: 59
Study 27676634 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg oral D2 agonist bromocriptine
Number of subjects: 18
Study 27676634 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mg oral haloperidol
Number of subjects: 18
Study 27676634 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 18
Study 25652002 — intervention group
Group type: EXPERIMENTAL
Intervention: Tango dancing
Number of subjects: 120
Study 25652002 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training
Number of subjects: 120
Study 25652002 — intervention group
Group type: COMPARATOR
Intervention: Stretching (control)
Number of subjects: 120
Study 24180001 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination ART and maraviroc
Number of subjects: 13
Study 24180001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 16441740 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% minocycline gel
Number of subjects: 40
Study 16441740 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing only (debridement)
Number of subjects: 40
Study 12900741 — intervention group
Group type: EXPERIMENTAL
Intervention: Tl-201 SPECT in patients with ischemic cardiomyopathy
Number of subjects: 29
Study 10731775 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 0
Study 10731775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8856421 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine treatment (4 weeks duration)
Number of subjects: 40
Study 8856421 — intervention group
Group type: COMPARATOR
Intervention: Placebo washout
Number of subjects: 40
Study 1622639 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC monthly (5-fluorouracil 500 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 500 mg/m2)
Number of subjects: 174
Study 1622639 — intervention group
Group type: COMPARATOR
Intervention: FEC weekly (5-fluorouracil 500 mg/m2, epirubicin 60 mg/m2, cyclophosphamide 500 mg/m2)
Number of subjects: 174
Study 1622639 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC monthly
Number of subjects: 174
Study 1622639 — intervention group
Group type: COMPARATOR
Intervention: FEC weekly
Number of subjects: 174
Study 6469175 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline sodium glycinate
Number of subjects: 6
Study 6469175 — intervention group
Group type: COMPARATOR
Intervention: Theophylline ethylenediamine
Number of subjects: 6
Study 31113214 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability education program including bedside teaching of physical examination/interview skills and case‐based discussion
Number of subjects: 23
Study 31113214 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability education program
Number of subjects: 23
Study 31113214 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 23
Study 28527926 — intervention group
Group type: EXPERIMENTAL
Intervention: TEVAR (Bolton Relay Thoracic Stent Graft)
Number of subjects: 120
Study 28527926 — intervention group
Group type: EXPERIMENTAL
Intervention: TEVAR (Relay Plus Delivery System)
Number of subjects: 120
Study 25881576 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity CRRT (40 mL/kg per hour)
Number of subjects: 24
Study 25881576 — intervention group
Group type: COMPARATOR
Intervention: Lower intensity CRRT (25 mL/kg per hour)
Number of subjects: 24
Study 22721550 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sleep
Number of subjects: 19
Study 22721550 — intervention group
Group type: COMPARATOR
Intervention: 27h total sleep deprivation
Number of subjects: 19
Study 22721550 — intervention group
Group type: EXPERIMENTAL
Intervention: PVT performance
Number of subjects: 19
Study 21185975 — intervention group
Group type: EXPERIMENTAL
Intervention: Choices nutrition logo used in intervention cafeterias (n=13) for a 3-week period.
Number of subjects: 368
Study 21185975 — intervention group
Group type: COMPARATOR
Intervention: Control cafeterias (n=12) without the Choices logo.
Number of subjects: 368
Study 21185975 — intervention group
Group type: EXPERIMENTAL
Intervention: Choices nutrition logo intervention.
Number of subjects: 368
Study 19336732 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose cruciferous diet
Number of subjects: 70
Study 19336732 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose cruciferous diet
Number of subjects: 70
Study 19336732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciferous plus apiaceous diet
Number of subjects: 70
Study 19336732 — intervention group
Group type: EXPERIMENTAL
Intervention: All vegetable-containing diets
Number of subjects: 70
Study 17785485 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 19979
Study 17785485 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 19979
Study 15566625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (6 g per day containing 1.5 g DHA)
Number of subjects: 0
Study 15566625 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6 g per day of olive oil)
Number of subjects: 0
Study 15566625 — intervention group
Group type: COMPARATOR
Intervention: No-treatment controls
Number of subjects: 0
Study 11678781 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate 100 mg on days -5, 1, and 5; artemisinin 500 mg on days 1 and 5.
Number of subjects: 20
Study 11678781 — intervention group
Group type: COMPARATOR
Intervention: Artemisinin 500 mg on days -5, 1, and 5; artesunate 100 mg on days 1 and 5.
Number of subjects: 20
Study 9577289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 0.5 mg/kg body weight twice a day for preterm infants
Number of subjects: 16
Study 9577289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 1.5 mg/kg body weight three times a day for term infants
Number of subjects: 16
Study 9577289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine treatment
Number of subjects: 16
Study 7870540 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal tests
Number of subjects: 109
Study 7870540 — intervention group
Group type: EXPERIMENTAL
Intervention: Field-independent students
Number of subjects: 109
Study 7870540 — intervention group
Group type: COMPARATOR
Intervention: Color coding
Number of subjects: 109
Study 3276111 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium heparin, 12,500 IU by the subcutaneous route
Number of subjects: 24
Study 3276111 — intervention group
Group type: COMPARATOR
Intervention: Placebo by the intramuscular route
Number of subjects: 24
Study 27888254 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerie Real images (not digitally modified)
Number of subjects: 200
Study 27888254 — intervention group
Group type: COMPARATOR
Intervention: Digitally modified images from previous campaigns
Number of subjects: 200
Study 28856854 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound (HIFU)
Number of subjects: 166
Study 28856854 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic myomectomy (LM)
Number of subjects: 166
Study 26887879 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable domestic pelvic floor neuromuscular electrical stimulation for 12 weeks after 4 weeks of hospital treatment
Number of subjects: 60
Study 26887879 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor electrophysiological treatment in hospital for 4 weeks
Number of subjects: 60
Study 26887879 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable domestic pelvic floor neuromuscular electrical stimulation
Number of subjects: 60
Study 23473546 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine (ASE)
Number of subjects: 960
Study 23473546 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLA)
Number of subjects: 960
Study 23473546 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 960
Study 21499083 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005%
Number of subjects: 69
Study 21499083 — intervention group
Group type: EXPERIMENTAL
Intervention: travoprost 0.004%
Number of subjects: 69
Study 21499083 — intervention group
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Number of subjects: 69
Study 19107187 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual training with six highly similar bird types; specific details on dosage and duration not available.
Number of subjects: 0
Study 19107187 — intervention group
Group type: COMPARATOR
Intervention: Visual training with similar birds without established category-boundaries; specific details on dosage and duration not available.
Number of subjects: 0
Study 16597717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive strategy aiming for the neighboring clockwise target (45 degrees away)
Number of subjects: 0
Study 16597717 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit adaptation to the neighboring target
Number of subjects: 0
Study 15357562 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration (IV group, n = 25): ketamine 1 mg/kg and midazolam 0.05-0.1 mg/kg
Number of subjects: 73
Study 15357562 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration (PO group, n = 24): ketamine 3 mg/kg and midazolam 0.5 mg/kg
Number of subjects: 73
Study 15357562 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration (PR group, n = 24): ketamine 3 mg/kg and midazolam 0.5 mg/kg
Number of subjects: 73
Study 11128861 — intervention group
Group type: EXPERIMENTAL
Intervention: Female cohort
Number of subjects: 19
Study 11128861 — intervention group
Group type: COMPARATOR
Intervention: Male cohort
Number of subjects: 19
Study 11128861 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cohorts
Number of subjects: 19
Study 9344294 — intervention group
Group type: EXPERIMENTAL
Intervention: Parastep 1 ambulation system training (32 sessions)
Number of subjects: 16
Study 1443450 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine 60 mg daily
Number of subjects: 24
Study 1443450 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine 120 mg daily
Number of subjects: 24
Study 1443450 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine 180 mg daily
Number of subjects: 24
Study 1443450 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine (all doses)
Number of subjects: 24
Study 1443450 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 2410979 — intervention group
Group type: EXPERIMENTAL
Intervention: TURP
Number of subjects: 75
Study 2410979 — intervention group
Group type: COMPARATOR
Intervention: TVP
Number of subjects: 75
Study 30024215 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobehavioral intervention (BBI) implemented by newly trained providers
Number of subjects: 158
Study 29090982 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dose (HD) influenza vaccine (Fluzone® High-Dose)
Number of subjects: 2957
Study 29090982 — intervention group
Group type: COMPARATOR
Intervention: Standard-Dose (SD) influenza vaccine (Fluzone®)
Number of subjects: 2957
Study 26682921 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised mixed‐sex cardiac rehabilitation
Number of subjects: 169
Study 26682921 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised women‐only cardiac rehabilitation
Number of subjects: 169
Study 26682921 — intervention group
Group type: EXPERIMENTAL
Intervention: Home‐based cardiac rehabilitation
Number of subjects: 169
Study 26682921 — intervention group
Group type: COMPARATOR
Intervention: Overall program adherence
Number of subjects: 169
Study 26682921 — intervention group
Group type: COMPARATOR
Intervention: Functional capacity preprogram to postprogram
Number of subjects: 169
Study 24249700 — intervention group
Group type: EXPERIMENTAL
Intervention: GBV-C viremia present
Number of subjects: 288
Study 24249700 — intervention group
Group type: COMPARATOR
Intervention: No GBV-C viremia
Number of subjects: 288
Study 24249700 — intervention group
Group type: EXPERIMENTAL
Intervention: GBV-C viremia
Number of subjects: 288
Study 24249700 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 count <100/mm(3) with GBV-C
Number of subjects: 288
Study 24249700 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 count
Number of subjects: 288
Study 22194630 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intervention (n = 425)
Number of subjects: 1270
Study 22194630 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity intervention (n = 421)
Number of subjects: 1270
Study 22194630 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 424)
Number of subjects: 1270
Study 22194630 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1270
Study 20042925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rehydration
Number of subjects: 11
Study 20042925 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rehydration
Number of subjects: 11
Study 20042925 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and IV combined rehydration
Number of subjects: 11
Study 20042925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum rehydration
Number of subjects: 11
Study 20042925 — intervention group
Group type: COMPARATOR
Intervention: All trials (IV, oral, oral and IV combined, ad libitum)
Number of subjects: 11
Study 18005804 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy for 45 minutes
Number of subjects: 66
Study 18005804 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted rest period for 45 minutes
Number of subjects: 66
Study 16076543 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received 2.5 days training on intercultural communication and patients were exposed to a videotaped instruction in the waiting room before consultation.
Number of subjects: 162
Study 16076543 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received 2.5 days training on intercultural communication.
Number of subjects: 162
Study 12185428 — intervention group
Group type: EXPERIMENTAL
Intervention: High respiratory rate (30 breaths/min)
Number of subjects: 10
Study 10687110 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg once a day
Number of subjects: 41
Study 10687110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 10687110 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 41
Study 8758156 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 0.5 mg
Number of subjects: 11
Study 8758156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 8758156 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 11
Study 1837744 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment with 1600 micrograms salbutamol or 160 micrograms ipratropium bromide daily
Number of subjects: 223
Study 1837744 — intervention group
Group type: COMPARATOR
Intervention: On demand treatment with salbutamol or ipratropium bromide during exacerbations or periods of dyspnoea
Number of subjects: 223
Study 1837744 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment
Number of subjects: 223
Study 1837744 — intervention group
Group type: COMPARATOR
Intervention: On demand treatment
Number of subjects: 223
Study 1837744 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol and ipratropium bromide
Number of subjects: 223
Study 6785100 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (75 mg/day for 3 days)
Number of subjects: 8
Study 29218366 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical donor natural killer (NK) cell therapy with rituximab and IL‐2 (NK dose 0.5‐3.27 × 107 NK cells/kg)
Number of subjects: 14
Study 29218366 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical donor natural killer (NK) cell therapy
Number of subjects: 14
Study 28528570 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week hypnosis intervention
Number of subjects: 172
Study 28528570 — intervention group
Group type: COMPARATOR
Intervention: Structured attention counseling
Number of subjects: 172
Study 26669859 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) with continuous femoral nerve block (FNB)
Number of subjects: 34
Study 26669859 — intervention group
Group type: COMPARATOR
Intervention: Sciatic nerve block (SNB) with continuous femoral nerve block (FNB)
Number of subjects: 34
Study 23402476 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg) / Hydrochlorothiazide (HCTZ, 12.5 mg)
Number of subjects: 0
Study 23402476 — intervention group
Group type: COMPARATOR
Intervention: ARB + Calcium Channel Blocker (CCB)
Number of subjects: 0
Study 21219118 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D fluoroscopic navigated reaming
Number of subjects: 10
Study 21219118 — intervention group
Group type: COMPARATOR
Intervention: Freehand group (control)
Number of subjects: 10
Study 17920723 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 100mg orally daily with carboplatin and etoposide every 3 weeks for 6 cycles, followed by maintenance thalidomide for up to 2 years
Number of subjects: 25
Study 16549263 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M-group (measurements at baseline, 2 and 6 months)
Number of subjects: 635
Study 16549263 — intervention group
Group type: COMPARATOR
Intervention: 1M-group (measurements only at 6 months)
Number of subjects: 635
Study 11914403 — intervention group
Group type: EXPERIMENTAL
Intervention: Current consulters (48% of migraine sufferers)
Number of subjects: 568
Study 11914403 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapsed consulters (21% of migraine sufferers)
Number of subjects: 568
Study 11914403 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall migraine sufferers
Number of subjects: 568
Study 11914403 — intervention group
Group type: EXPERIMENTAL
Intervention: Current or lapsed consulters
Number of subjects: 568
Study 11914403 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall migraine prevalence
Number of subjects: 568
Study 9791750 — intervention group
Group type: EXPERIMENTAL
Intervention: BacT/Alert aerobic FAN bottle
Number of subjects: 243
Study 9791750 — intervention group
Group type: COMPARATOR
Intervention: Standard anaerobic bottle
Number of subjects: 243
Study 8541573 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 30
Study 8541573 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg
Number of subjects: 30
Study 8541573 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study 8541573 — intervention group
Group type: COMPARATOR
Intervention: Baseline conditions
Number of subjects: 30
Study 2796346 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea plus pelvic irradiation
Number of subjects: 25
Study 2796346 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus pelvic irradiation
Number of subjects: 25
Study 961726 — intervention group
Group type: EXPERIMENTAL
Intervention: Massed-demonstration trials with verbalization
Number of subjects: 48
Study 961726 — intervention group
Group type: EXPERIMENTAL
Intervention: Massed trials without verbalization
Number of subjects: 48
Study 961726 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed-demonstration trials with verbalization
Number of subjects: 48
Study 961726 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed trials without verbalization
Number of subjects: 48
Study 7027891 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg once daily
Number of subjects: 20
Study 7027891 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg once daily
Number of subjects: 20
Study 7027891 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg Durules once daily
Number of subjects: 20
Study 7027891 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 200 mg conventional tablets
Number of subjects: 20